$NUVL

Oliger Christy J. sold (to issuer) 6,091 shares of NUVL

Oliger Christy J. sold (to issuer) 6,091 shares of Nuvalent, Inc. (NUVL) on 2026-07-15.

Original reporting
SEC EDGAR · Oliger Christy J.
Published Jul 15, 2026, 11:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
low confidence
Mentioned
$NUVL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

The filing confirms the director’s direct holdings dropped to zero via a sale to the issuer; it does not include any new company performance, guidance, or regulatory/clinical catalyst.

02

Market read

Traders may note insider selling to issuer and the director exiting direct ownership, but the lack of price and absence of fundamental updates limits tradable impact.

03

What to watch

No price is disclosed and there is no 10b5-1 plan stated; without context on the issuer’s buyback program or director compensation structure, signal strength is weak.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-15 after-hours (SEC Form 4)

Background

This is an SEC Form 4 insider transaction for Nuvalent, Inc., reported as a sale to the issuer by a director.

Company-level read

Ticker impact

$NUVLNeutralLow confidence
Context

Nuvalent director Oliger Christy J. sold 6,091 shares to the issuer on 2026-07-15, with post-sale holdings at 0 shares.

Expected impact

Low near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 shows a small, non-price-disclosed transaction and indicates the director ended direct ownership, but it does not provide new operating or financial information.

Market effects

No clear sector read-through from a single director sale to issuer.

None.

None.

Counterpoint

A sale to the issuer can be mechanical (e.g., buyback participation or plan mechanics), so it may not reflect bearish fundamentals.

Key entities

  • Nuvalent, Inc.

    Subject of the Form 4 insider transaction; director sold 6,091 shares to the issuer and ended with 0 shares.

  • Oliger Christy J.

    Director who sold 6,091 shares to the issuer on 2026-07-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.